linjc16/ctgov huggingface dataset:
Genotoxicity Assessment for Patients Undergoing Radiation Treatment

Study Overview
=================
Brief Summary
-----------------
The purpose of the research study is to evaluate an automated, laser-based technique for measuring DNA damage caused by radiation during cancer treatment in immature red blood cells.

Detailed Description
-----------------
Correlative studies: analysis of RT effect on genotoxicity by assessing cytogenetic changes (dicentrics), micronucleated lymphocytes (MN-lymph), and micronucleated reticulocytes (MN-RET) using peripheral blood of patients receiving radiation. i) document the kinetics by which radiation-induced MN-RET enter the peripheral blood stream. ii) benchmark the MN-RET endpoint against current gold-standard biodosimetry endpoints-dicentrics and MN-lymphocytes. iii) measure inter-individual variation in baseline and radiation-induced MN-RET frequencies. iv) in collaboration with several FCM-equipped laboratories, evaluate the transferability of the human MN-RET scoring assay.

Official Title
-----------------
Genotoxicity Assessment for Patients Receiving Large Field Irradiation

Conditions
-----------------
Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients that are scheduled to begin radiotherapy to the large-field chest region are eligible if: Daily radiation dose is between 1.8 and 5 Gy/day Any single dimension of field size is ≥ 15 cm Provision of written informed consent or Or patients receiving IMRT or Tomotherapy, when low-dose radiation is spread out to the normal tissues, irrespective of daily radiation doses. Or patients receiving radionucleotides as part of the medical treatment (cancer or non-malignant conditions) Or patients who will receive diagnostic CT scans, PET/CT scans, mammograms, or diagnostic imaging requiring radionucleotides

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure the Change in MN-RET in the blood |  | Baseline and 1 day |
Free Fatty Acids: Short Exposure Study

Study Overview
=================
Brief Summary
-----------------
This study will examine whether or not short, daily exposures change a person's ability to detect free fatty acids in a solution by its taste. Repeated exposure should improve a person's ability to detect free fatty acids.

Detailed Description
-----------------
The possibility that humans can taste non-esterified fatty acids (NEFA) - so-called fat taste - is a relatively new area of research. Previous work suggests that subjects require an average of between two and three testing sessions of approximately an hour each before they can reliably detect NEFA, and the average number of visits to get the lowest threshold is six. Streamlining this process is of great interest to researchers who wish to test many people as quickly as possible. Other taste qualities, including umami and sweet, have shown improvement in detection sensitivity in subjects that have undergone ten second exposures to these taste qualities for 10 days upon subsequent re-testing. We seek to determine if the same improvements can be seen with fat taste.

Official Title
-----------------
Free Fatty Acids: Short Exposure Study

Conditions
-----------------
Hypogeusia

Intervention / Treatment
-----------------
* Other: NEFA
* Other: Sucrose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: good health available for multiple testing visits Exclusion Criteria: have participated in a fat taste study in the past 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NEFA<br>Participants swish and spit 5 mL of an oleic acid solution everyday for 10 days. | Other: NEFA<br> <br> * Other names: Oleic acid;|
| Active Comparator: Control<br>Participants swish and spit 5 mL of sucrose solution everyday for 10 days. | Other: Sucrose<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NEFA detection threshold |  | 10 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hunger | Visual analog scale assessment of hunger level prior to testing | 2 days | 
| BMI |  | 1 day | 
| Taste descriptor | Description of NEFA taste by participant, e.g., sour, bitter, etc. | 10 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Taste, Fat Taste, Threshold Testing
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Study Overview
=================
Brief Summary
-----------------
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Official Title
-----------------
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Conditions
-----------------
Leukemia, Myeloid, Chronic

Intervention / Treatment
-----------------
* Drug: Glivec®/Gleevec®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Imatinib (Glivec/Gleevec) Resistant or Intolerant CML in Blast Crisis, Accelerated Phase or Chronic Phase
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Glivec®/Gleevec®|Chemotherapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effectiveness |  | overall | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CML in Blast Crisis, Accelerated Phase oe Chronic Phase
A Multi-center, Comparative Clinical Trial to Evaluate the Efficacy and Safety of Inject BMP in Patients Undergoing Transforaminal Lumbar Interbody Fusion

Study Overview
=================
Brief Summary
-----------------
A Randomized, Subject-Assessor Blind, Multi-center, Comparative Clinical Trial to evaluate the efficacy and safety of Inject BMP in Patients Undergoing Transforaminal Lumbar Interbody Fusion.

Conditions
-----------------
Transforaminal Lumbar Interbody Fusion

Intervention / Treatment
-----------------
* Device: Inject BMP
* Procedure: Locally Harvested Bone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The subject needs the infusion between the first lumbar vertebrato and the first ilium from those who require posterior spinal instrumentation and interbody fusion for the following reasons, Spinal stenosis Spinal disc herniation requiring broad laminectomy Spondylolisthesis or spondylolysis Recurrent herniated disc Exclusion Criteria: Patients with BMD T-score < -3.0 Women who are pregnant or plan to be pregnant within study period

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Inject BMP<br>ExcelOS Inject / rhBMP-2 | Device: Inject BMP<br> <br> |
| Active Comparator: Locally Harvested Bone<br>Locally Harvested Bone | Procedure: Locally Harvested Bone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone Fusion With CT and Dynamic radiographs(X-ray)(post operative 48 weeks) |  | at 48 weeks after surgery |
Community Based Strategies for Early Detection of Melanoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to pilot the use of community education and digital dermatology to increase the early detection of curable melanomas.

Official Title
-----------------
A Pilot Feasibility Study of Community Based Strategies for Early Detection of Melanoma

Conditions
-----------------
Melanoma

Intervention / Treatment
-----------------
* Behavioral: Community Based Strategies for Early Detection of Melanoma


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and older >1mm lesion thickness with ulceration (T2b) or >2mm lesion thickness (T3/T4) Low socioeconomic status (SES) Non-Latinx White individuals (according to Yost's index SES level based on a principal components analysis) Latinx individuals Individual resides in semi-rural area, including zip codes within Antelope Valley in Southern California and Salinas in Northern California Individual speaks and reads English or Spanish Voluntary willingness and comprehension to consent Exclusion Criteria: Exclusion criteria is stage 0, I, IV, or unstaged diagnosis, or any individual who does not meet the above stated eligibility criteria will be excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Community Based Strategies for Early Detection of Melanoma|The main procedures of this study include educational sessions about melanoma and how to detect it at its earliest stages with the help of a community health worker, conducting a self-skin examination every three months, helping to perform a skin examination every three months for a family member or friend who would be selected as a partner, and completing short questionnaires at the beginning of the study, at month three during the study, and at completion of the study.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Completion of self and partner skin examinations | Proportion of individuals recruited to those that follow through with the protocol | 3 months | 
| Completion of self and partner skin examinations | Proportion of individuals recruited to those that follow through with the protocol | 6 months |
Half-Dose Flu Vaccine Study in Healthy Adults

Study Overview
=================
Brief Summary
-----------------
It appears likely that there will be a delay and possibly a reduction in the amount of influenza vaccine available for the 2000-2001 influenza season. One possible way of increasing the availability of influenza vaccine for this year is to use a half-dose in healthy adults. The objective of this study is to determine if the immune system responds to a half-dose the same way it responds to a whole dose. This study will use the currently approved inactivated influenza vaccine in healthy adults ages 18 to 49 years old. If the immune response to the half-dose is not significantly different than the immune response generated to the whole dose, this could be a strategy to extend the amount of vaccine that could be available in this age group.

Detailed Description
-----------------
Eligible subjects will be randomized to receive a single intramuscular injection of either a half-dose or a whole dose of a currently approved influenza virus vaccine in their arm. Prior to vaccination, subjects will have one tube of blood drawn. Subjects will be given a 3-day diary card to record any symptoms they may experience and asked to return for a second and final visit approximately 21 days following vaccination. A second blood draw will be done.

Official Title
-----------------
Evaluation of the Immunogenicity of Low Dose Trivalent Inactivated Influenza Vaccine in Healthy Adults

Conditions
-----------------
Influenza

Intervention / Treatment
-----------------
* Biological: Approved influenza virus vaccine.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteers may be eligible for this trial if they: Are able to and have given informed consent. Are able to understand and comply with all study procedures and to complete study diary. Are aged 18 to 49 years. Are female, and are not pregnant. Are available for all study visits. Exclusion Criteria: Volunteers will not be eligible for this trial if they: Are allergic to eggs or egg products. Have a current chronic medical condition for which influenza vaccine is normally recommended. Have received experimental vaccines or medications within 30 days of study entry. Have received parenteral immunoglobulin within 30 days of study entry.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Approved influenza virus vaccine.|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Relationship Between Social Status and Use of Healthcare Services During the Confinement Period Linked to the COVID-19 Epidemic

Study Overview
=================
Brief Summary
-----------------
Epidemics have always affected the most disadvantaged social categories more intensely. This social inequality is expressed in the use of care and emergencies: greater frequency but also greater seriousness. Our hypothesis is that, during a period of confinement, the most disadvantaged populations are more affected by the COVID-19 infection than the rest of the population. The number of remedies is greater, as is the severity of the forms of infection.

Official Title
-----------------
Retrospective Study on the Relationship Between Social Status and Use of Healthcare Services During the Confinement Period Linked to the COVID-19 Epidemic in Bas-Rhin, France

Conditions
-----------------
Covid-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female aged 18 or over Calling center 15 from March 17 at noon and until the end of the confinement period (May 31, 2020) for one of the following reasons that may be related to COVID-19: cough, fever, rhinitis, diarrhea, pain thoracic, odynophagia, diarrhea, anosmia, ageusia, whose calling address belongs to Bas-Rhin Or Supported (consultation or hospitalization) at the HUS for a COVID-19 infection and included in the COVID-HUS base and residing in the Bas-Rhin. Exclusion Criteria: Patient under the protection of justice Patient under guardianship, curatorship Patient taken care of at the screening center

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective study on the relationship between social status and use of healthcare services during the confinement period linked to the COVID-19 epidemic in Bas-Rhin, France |  | Files analysed retrospectily from March 17, 2020 to May 31, 2020 will be examined] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Coronavirus, Sars-cov-2
Maternal Periodontal Status and Cytokines in Preeclampsia

Study Overview
=================
Brief Summary
-----------------
Background: The purpose of this study is to examine the relationship between maternal preeclampsia and periodontal parameters and the correlation of these two disorders with maternal gingival crevicular fluid levels (GCF) of interleukin (IL)-35, interleukin-37 and interleukin-6. The investigators also investigated their relation to the severity of preeclampsia. Methods: 82 preeclamptic women were recruited to the study (29 healthy pregnant women, 30 mild preeclamptic patient, 23 severe preeclamptic patient ). The clinical periodontal parameters and GCF samples were collected in the first day of puerperium.

Official Title
-----------------
Maternal Periodontal Status and Gingival Crevicular Fluid Levels of Interleukin-6, Interleukin-35, and Interleukin-37 in Preeclampsia

Conditions
-----------------
Preeclampsia, Periodontal Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: gingival crevicular fluid collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged between 18 and 45 years 25 and 40 weeks of gestation. Healthy pregnants, mild and severe preeclampsia Exclusion Criteria: Patients with accompanying diseases multiple gestations congenital abnormalities were excluded from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy pregnants<br> | Diagnostic Test: gingival crevicular fluid collection<br> <br> |
| mild preeclampsia<br> | |
| severe preeclampsia<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| maternal periodontal clinical parameters and IL-37 and IL-35 and IL-6 levels | IL-37 IL-35 and IL-6 levels in maternal gingival crevicular fluid levels between the three groups | 6 months |
Applications of Realtime Functional Magnetic Resonance Imaging (fMRI )

Study Overview
=================
Brief Summary
-----------------
The goal of this research program is to determine the potential effectiveness of real-time fMRI training in improving mental control over pain.

Detailed Description
-----------------
A research study that looks at pain and how you experience pain. This research project aims to use virtual reality-based real-time functional Magnetic Resonance Imaging (rtfMRI) to assess brain activation during the experience of pain and while subjects attempt to mentally control their pain response.

Official Title
-----------------
Applications of Realtime fMRI Phase II

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Procedure: Real-time fMRI feedback


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-65 Chronic Pain patient or healthy control Ability to perform the experimental task Exclusion Criteria: MRI contraindication (metal implants, claustrophobia, pregnant or planning to become pregnant) History of psychiatric disorder (at the discretion of the investigator as to whether it interferes with the experimental task) History of Blistering

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Real-Time fMRI<br>Real-Time fMRI | Procedure: Real-time fMRI feedback<br>* Patients receive real-time fMRI biofeedback to modulate pain<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain reduction as measured by visual analog scale (VAS) pain report |  | Within the 2 hour feedback session | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Control of brain activity as measured by fMRI analysis |  | Within the 2 hour feedback session |
Whole Exome Sequencing of Familial and Pediatric Forms of Vasculitis

Study Overview
=================
Brief Summary
-----------------
The FAMILYVASC study is a prospective observational study which will aim to identify susceptibility loci and genes for systemic vasculitis risk in patients with familial or pediatric forms of vasculitis. Genetic analysis based on whole exome sequencing will be carried out through salivary DNA.

Official Title
-----------------
Identification of Susceptibility Loci and Genes for Systemic Vasculitis Risk, by Analyzing Whole Exome Sequencing of Familial and Pediatric Forms of Vasculitis (FAMILYVASC Study)

Conditions
-----------------
Vasculitis

Intervention / Treatment
-----------------
* Genetic: genetic analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria for subjects with vasculitis Children and adults Patients with vasculitis, as defined in the Chapel Hill International Classification in its revised version of 2012 Patient information and signed informed consent Pregnant and breastfeeding women can be included in the study Inclusion criteria for healthy subjects Children and adults Do not have vasculitis, as defined in the Chapel Hill International Classification in its revised version of 2012, or relatives on the 1st; 2nd; 3rd or 4th degree of a patient with vasculitis Patient information and signed informed consent Pregnant and breastfeeding women can be included in the study Exclusion criteria: Refusal of consent or inability to obtain consent Dementia or unauthorized patient, for psychiatric or intellectual failure reasons, to receive information about the protocol and to give informed consent. Uncooperative patient, or any pathology that could make the patient potentially non-compliant to the study procedures, and patients interned for regulatory or legal reasons.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: genetic analysis|Saliva sample collection for genetic analysis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of susceptibility loci and genes |  | At the moment of enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vasculitis